
The FDA has chosen to award Novartis’ Adakveo (crizanlizumab) with marketing authorisation, it has emerged, as a treatment to reduce …
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ

